JP2023508165A5 - - Google Patents
Info
- Publication number
- JP2023508165A5 JP2023508165A5 JP2022538879A JP2022538879A JP2023508165A5 JP 2023508165 A5 JP2023508165 A5 JP 2023508165A5 JP 2022538879 A JP2022538879 A JP 2022538879A JP 2022538879 A JP2022538879 A JP 2022538879A JP 2023508165 A5 JP2023508165 A5 JP 2023508165A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- expression
- mdm2 antagonist
- bap1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025122610A JP2025160292A (ja) | 2019-12-23 | 2025-07-22 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1919219.4 | 2019-12-23 | ||
| GBGB1919219.4A GB201919219D0 (en) | 2019-12-23 | 2019-12-23 | Cancer biomarkers |
| PCT/IB2020/062366 WO2021130682A2 (en) | 2019-12-23 | 2020-12-23 | Biomarkers for cancer therapy using mdm2 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122610A Division JP2025160292A (ja) | 2019-12-23 | 2025-07-22 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508165A JP2023508165A (ja) | 2023-03-01 |
| JP2023508165A5 true JP2023508165A5 (enExample) | 2024-01-09 |
Family
ID=69322948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538879A Pending JP2023508165A (ja) | 2019-12-23 | 2020-12-23 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
| JP2025122610A Pending JP2025160292A (ja) | 2019-12-23 | 2025-07-22 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122610A Pending JP2025160292A (ja) | 2019-12-23 | 2025-07-22 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230338337A1 (enExample) |
| EP (1) | EP4081801A2 (enExample) |
| JP (2) | JP2023508165A (enExample) |
| KR (1) | KR20220119423A (enExample) |
| CN (1) | CN115066614A (enExample) |
| AU (1) | AU2020414482A1 (enExample) |
| BR (1) | BR112022012444A2 (enExample) |
| CA (1) | CA3162624A1 (enExample) |
| GB (1) | GB201919219D0 (enExample) |
| IL (1) | IL293934A (enExample) |
| MX (1) | MX2022007876A (enExample) |
| PH (1) | PH12022551443A1 (enExample) |
| TW (1) | TW202135803A (enExample) |
| WO (1) | WO2021130682A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CA3240356A1 (en) * | 2017-11-30 | 2019-06-06 | Jazz Pharmaceuticals Ireland Ltd. | Methods of treatment with asparaginase |
| EP4204812A2 (en) | 2020-08-27 | 2023-07-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
| GB202103080D0 (en) * | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| JP2024530943A (ja) * | 2021-08-06 | 2024-08-27 | アンスティテュ・レジオナル・デュ・カンセール・ドゥ・モンペリエ | がんの処置のための方法 |
| KR20240156407A (ko) * | 2022-03-04 | 2024-10-29 | 오츠카 세이야쿠 가부시키가이샤 | Iap 길항제 화합물과 조합 요법을 이용한 암 치료 방법 |
| US20240217985A1 (en) * | 2022-12-22 | 2024-07-04 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF AN MDM2-p53 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS |
| WO2024141014A1 (zh) * | 2022-12-30 | 2024-07-04 | 康方药业有限公司 | Cd74的医药用途 |
| WO2025235391A1 (en) * | 2024-05-06 | 2025-11-13 | University Of Massachusetts | P53 protein stabieizers inceuding mdm2 inhibitors as a "chemicae mastectomy" strategy in breast cancer brca1/2 mutation carriers |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| CA2262479A1 (en) * | 1996-08-02 | 1998-02-12 | The Wistar Institute Of Anatomy And Biology | Brca1 associated protein (bap-1) and uses therefor |
| UA107814C2 (uk) | 2009-11-12 | 2015-02-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи мdм2 |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US10344333B2 (en) | 2011-02-18 | 2019-07-09 | Institute For Cancer Research | Methods for diagnosing a predisposition to develop cancer |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| EP2958893B1 (en) | 2013-02-21 | 2017-05-03 | F. Hoffmann-La Roche AG | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| BR112015029976A2 (pt) | 2013-06-24 | 2017-07-25 | Hoffmann La Roche | formulação farmacêutica, formulação liofilizada farmacêutica e preparações novas, métodos e usos |
| SG11201510816SA (en) * | 2013-07-03 | 2016-01-28 | Hoffmann La Roche | Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist |
| KR20220136454A (ko) | 2013-09-04 | 2022-10-07 | 다이이찌 산쿄 가부시키가이샤 | 스피로옥시인돌 유도체의 제조 방법 |
| US9657351B2 (en) * | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| BR122022015241B1 (pt) * | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| CA2945527C (en) | 2014-04-17 | 2022-05-17 | The Regents Of The University Of Michigan | Mdm2 inhibitors and therapeutic methods using the same |
| EP3158086B1 (en) * | 2014-06-19 | 2021-03-24 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to ezh2 inhibitors |
| JP2017532959A (ja) | 2014-10-09 | 2017-11-09 | 第一三共株式会社 | Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| JP2019508406A (ja) | 2016-02-08 | 2019-03-28 | エピザイム，インコーポレイティド | 癌を処置する方法 |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| WO2017205786A1 (en) | 2016-05-27 | 2017-11-30 | Aileron Therapeutics, Inc. | Cell permeable peptidomimetic macrocycles |
| GB201615842D0 (en) | 2016-09-16 | 2016-11-02 | Ucl Business Plc | Cell death biomarker |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
-
2019
- 2019-12-23 GB GBGB1919219.4A patent/GB201919219D0/en not_active Ceased
-
2020
- 2020-12-23 AU AU2020414482A patent/AU2020414482A1/en active Pending
- 2020-12-23 KR KR1020227024749A patent/KR20220119423A/ko active Pending
- 2020-12-23 WO PCT/IB2020/062366 patent/WO2021130682A2/en not_active Ceased
- 2020-12-23 MX MX2022007876A patent/MX2022007876A/es unknown
- 2020-12-23 JP JP2022538879A patent/JP2023508165A/ja active Pending
- 2020-12-23 IL IL293934A patent/IL293934A/en unknown
- 2020-12-23 TW TW109145725A patent/TW202135803A/zh unknown
- 2020-12-23 PH PH1/2022/551443A patent/PH12022551443A1/en unknown
- 2020-12-23 EP EP20830342.0A patent/EP4081801A2/en active Pending
- 2020-12-23 US US17/757,843 patent/US20230338337A1/en active Pending
- 2020-12-23 CA CA3162624A patent/CA3162624A1/en active Pending
- 2020-12-23 CN CN202080096246.7A patent/CN115066614A/zh active Pending
- 2020-12-23 BR BR112022012444A patent/BR112022012444A2/pt unknown
-
2025
- 2025-07-22 JP JP2025122610A patent/JP2025160292A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508165A5 (enExample) | ||
| JP7153775B2 (ja) | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 | |
| Moneta et al. | Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features | |
| US20220153855A1 (en) | Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease | |
| JP6038128B2 (ja) | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー | |
| EP2337864B1 (en) | Biomarkers for predicting the development of chronic autoimmune diseases | |
| JP2024508895A5 (enExample) | ||
| CA2988673A1 (en) | Epigenetic chromosome interactions | |
| Higham et al. | Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease | |
| TW201514310A (zh) | 發炎性疾病之抗－ｔｎｆ與抗－ｉｌ１７組合療法生物標記 | |
| JP2023539867A5 (enExample) | ||
| JP2021511389A (ja) | 脊髄性筋萎縮症を治療する方法 | |
| JP2026002914A (ja) | 乾癬治療における抗腫瘍壊死因子療法に対する応答性を判定するための方法 | |
| Pisani et al. | Proteomic insights on the metabolism in inflammatory bowel disease | |
| Bolko et al. | Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis | |
| de Montai et al. | Interferon-α biological activity is associated with disease activity and risk of flare in cutaneous lupus erythematosus: a monocentric study of 184 patients | |
| US20170145501A1 (en) | Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response | |
| EP3417291B1 (en) | Anti-cxc chemokine receptor antibodies and c-x-c chemokines for the diagnosis of autoimmune disease and graft-versus-host disease | |
| EP2954325B1 (en) | Diagnosis of rheumatoid arthritis | |
| Koca et al. | Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet's disease | |
| JP7016110B2 (ja) | スティル病と敗血症との鑑別用バイオマーカー | |
| Abd-Elghany et al. | Association of serum PYCARD and NLRP3 inflammasome gene polymorphism with rheumatoid arthritis and disease activity | |
| CN104105967A (zh) | 生腱蛋白c及其在类风湿关节炎的用途 | |
| US11779643B2 (en) | Methods and compositions for the treatment of an inflammatory bowel disease | |
| WO2018020060A1 (es) | Método para predecir la respuesta clínica a un tratamiento con agentes antiinflamatorios |